An observational study of clinical recurrence in patients with interstitial lung disease related to the antisynthetase syndrome.
Haoran ChenHuarui LiuWenting LyuYin LiuMei HuangYingwei ZhangYuying QiuYonglong XiaoHourong CaiJinghong DaiPublished in: Clinical rheumatology (2022)
Recurrence of ARS-ILD was common during medication intensity reduction. Age, LDH, medication tapering duration, and discontinuation were risk factors for recurrence. Further efforts to reduce recurrence should take into consideration of these factors. Key Points • Recurrence is observed commonly with a recurrency rate 52.3% in patients with interstitial lung disease related to antisynthetase syndrome (ARS-ILD) when glucocorticoids (GC) tapering or discontinuation. • Age, increased serum lactate dehydrogenase (LDH) level, medication tapering duration, and GC discontinuation were identified to be significantly associated with the recurrence of ARS-ILD.